1. Scrip
  2. >>Therapy Areas

AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal

Licenses Out Eklira and Duaklir For $270m

 
• By Kevin Grogan

Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.

Neon Light Sign Lungs Icon
• Source: Archive

AstraZeneca PLC has returned to its strategy of offloading non-core assets and teamed up again with Covis Pharma to find a new home for the respiratory drugs Eklira and Duaklir.

Luxembourg-based Covis is paying $270m to get hold of the global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium/formoterol) for chronic obstructive pulmonary disease (COPD). AstraZeneca bagged the rights to the two drugs through a deal inked with Almirall SA in 2014 which saw the Spanish company bank an upfront payment of $900m as it switched its focus from respiratory to dermatological disorders

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

More from Therapy Areas

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.